Latest news for A. Soriano (OTC:SRIOF) Stock

A. Soriano Corp is a holding company. It operates with various business segments such as the Holding Company segment, the Resort Operations segment is involved in hotel and resort accommodation, relaxation and entertainment, and construction and sale of villas, and the Cable and Wire Manufacturing segment is engaged in manufacturing, importing, exporting, buying and selling goods, such as building wires, power cables, aluminum wires, and cables and Other operations include air transportation, hangarage, real estate holding and management, and recruitment services. The majority of its revenue comes from the Cable and Wire Manufacturing segment.

A. Soriano Corp

News

Guidance

ALGT

Allegiant Travel Sees Q3 EPS $(3.50)-$(2.50) Vs $0.64 Est.

Third Quarter and Full Year 2024 Guidance
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Third Quarter 2024</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">Full Year 2024</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">$113 million to $114 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$442 million to $444 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Year-over-Year Growth %</td>
<td colspan="1" rowspan="1">~19% to 20%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">~20% to 21%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">$36 million</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">$140 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA Margin %</td>
<td colspan="1" rowspan="1">~32%</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">~32%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Equity-based compensation expense and related payroll taxes</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">~$106 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Depreciation and Amortization</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">~$12 million</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Non-GAAP effective tax rate</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">25&nbsp;%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Diluted non-GAAP share count</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1"> &nbsp;</td>
<td colspan="1" rowspan="1">~258 million&nbsp;&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Certain components of the guidance given above are provided on a non-GAAP basis only without providing a reconciliation to guidance provided on a GAAP basis. Information is presented in this manner because the preparation of such a reconciliation could not be accomplished without "unreasonable efforts." The Company does not have access to certain information that would be necessary to provide such a reconciliation, including non-recurring items that are not indicative of the Company's ongoing operations. The Company does not believe that this information is likely to be significant to an assessment of the Company's ongoing operations.

CWAN

Clearwater Analytics Sees Q3 Revenue $113M-$114M Vs $112.82M Est.; FY24 Revenue $442M-$444M Vs $440.35M Est.

American Water Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWK#NYSE">AWK</a>) reported quarterly earnings of $1.42 per share which missed the analyst consensus estimate of $1.46 by 2.74 percent. The company reported quarterly sales of $1.149 billion which beat the analyst consensus estimate of $1.115 billion by 3.10 percent. This is a 4.74 percent increase over sales of $1.097 billion the same period last year.

Earnings

Earnings Beats

Earnings Misses

American Water Works Q2 2024 GAAP EPS $1.42 Misses $1.46 Estimate, Sales $1.149B Beat $1.115B Estimate

Rush Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUSHB#NASDAQ">RUSHB</a>) reported quarterly earnings of $0.97 per share. This is a 17.09 percent decrease over earnings of $1.17 per share from the same period last year. The company reported $2.03 billion in sales this quarter. This is a 1.20 percent increase over sales of $2.00 billion the same period last year.

RUSHB

Rush Enterprises Q2 EPS $0.97 Down From $1.17 YoY, Sales $2.03B Up From $2.00B YoY

COHU

Cohu Expects Q3 Sales Of $95M +/- $5M; Est $107.2M

Vanda Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.21) by 61.9 percent. The company reported quarterly sales of $50.474 million which beat the analyst consensus estimate of $47.860 million by 5.46 percent. This is a 9.59 percent increase over sales of $46.056 million the same period last year.

VNDA

Vanda Pharma Q2 2024 GAAP EPS $(0.08) Beats $(0.21) Estimate, Sales $50.474M Beat $47.860M Estimate

Enact Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACT#NASDAQ">ACT</a>) reported quarterly earnings of $1.27 per share which beat the analyst consensus estimate of $0.99 by 28.28 percent. The company reported quarterly sales of $298.83 million which beat the analyst consensus estimate of $298.73 million by 0.03 percent. This is a 7.68 percent increase over sales of $277.52 million the same period last year.

Enact Holdings Q2 2024 Adj EPS $1.27 Beats $0.99 Estimate, Sales $298.83M Beat $298.73M Estimate

Mister Car Wash Reiterates 2024 Outlook, Sees Revenues $988M-$1.016B vs $998.11M Est., Adj. EPS $0.30-$0.34 vs $0.32 Est.

ACHC

Acadia Healthcare Sees FY24 Adj. EPS $3.45-$3.65 Vs $3.49 Est.; Revenue $3.180B-$3.22B Vs $3.202B Est.

CCRN

Cross Country Healthcare Sees Q3 2024 Adj. EPS $0.08-$0.12 Vs $0.13 Estimate

QIAGEN has updated its FY 2024 outlook based on the solid core business performance in the first half of the year, which was about $15 million CER above guidance, as well as the decision to phase out the NeuMoDx clinical PCR system. As a result, total net sales are expected to be at least $1.985 billion CER and includes a $30 million CER adjustment in expected NeuMoDx sales for 2024.
The outlook for adjusted diluted EPS has been increased to at least $2.16 CER, while the adjusted operating income margin target is for at least 28.5% compared to 26.9% in 2023.

QGEN

Qiagen Sees FY24 EPS $2.16 Vs $2.12 Est.; Revenue $1.985B Vs $2B Est.

Mister Car Wash (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCW#NYSE">MCW</a>) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.09 by 22.22 percent. The company reported quarterly sales of $255.000 million which missed the analyst consensus estimate of $255.331 million by 0.13 percent. This is a 7.64 percent increase over sales of $236.894 million the same period last year.

Mister Car Wash Q2 2024 Adj. EPS $0.11 Beats $0.09 Estimate, Sales $255.000M Miss $255.331M Estimate

<ul>
<li>Raises full-year adjusted EBITDA&nbsp;guidance&nbsp;midpoint by&nbsp;$8M.</li>
</ul>

EXAS

Exact Sciences Maintains Full-year 2024 Revenue Guidance Of $2.81B - $2.85B, Est $2.829B

Cross Country Healthcare Sees Q3 2024 Revenue $305M-$315M Vs $334.7M Estimate

Axcelis Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACLS#NASDAQ">ACLS</a>) reported quarterly earnings of $1.55 per share which beat the analyst consensus estimate of $1.35 by 14.81 percent. The company reported quarterly sales of $256.512 million which beat the analyst consensus estimate of $250.302 million by 2.48 percent. This is a 6.37 percent decrease over sales of $273.970 million the same period last year.

ACLS

Axcelis Technologies Q2 2024 GAAP EPS $1.55 Beats $1.35 Estimate, Sales $256.512M Beat $250.302M Estimate

EVTC

Evertec Sees FY24 Revenue $846M-$854M vs $850.49M Est., Adj. EPS $2.98-$3.07 vs $2.90 Est.

Cross Country Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCRN#NASDAQ">CCRN</a>) reported quarterly earnings of $0.10 per share which missed the analyst consensus estimate of $0.13 by 23.08 percent. The company reported quarterly sales of $339.77 million which beat the analyst consensus estimate of $334.76 million by 1.50 percent. This is a 37.16 percent decrease over sales of $540.70 million the same period last year.

Cross Country Healthcare Q2 2024 Adj EPS $0.10 Misses $0.13 Estimate, Sales $339.77M Beat $334.76M Estimate

JAZZ

Jazz Pharmaceuticals Sees FY24 Adj EPS $19.20-$20.30 Vs $18.51 Est.; Revenue $4.0B-$4.1B Vs $4.047B Est.

2024 Revenue Guidance
The company expects 2024 net sales to be in the range of $370 million to $376 million based on the latest foreign currency exchange rates.

GKOS

Glaukos Sees FY24 Revenue $370M-$376M Vs $363.02M Est.

Kilroy Realty Corporation Updates 2024 Nareit-Defined FFO Guidance to $4.21-$4.31 Per Share; Midpoint Now $4.26; Raises Net Income Guidance to $1.50-$1.59 Per Share; Adjusts Key Assumptions for NOI, Occupancy, and Development Spending

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

A. Soriano

News

Latest news for A. Soriano (OTC:SRIOF) Stock